Insider / RESMED INC
FARRELL PETER C
Director at RESMED INC
- Company
- RESMED INC
- Ticker
- RMD
- First filing on record
- August 6, 2026
- Latest trade on record
- September 2, 2026
- SEC filings
- EDGAR ↗
FARRELL PETER C, Director at RESMED INC, has disclosed 2 transactions in RMD since August 6, 2026: 0 purchases (0 open-market buys) and 2 sales, worth about $2.0M at the reported prices. The latest was filed September 4, 2026, 2 days after the trade.
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
In the last 12 months FARRELL PETER C made no purchases and 2 sales worth $2.0M. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
FARRELL PETER C has traded 1 stock on record; the largest by dollars is RMD.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 2 | 8,970 | $2.0M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 2 · $2.0M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| RMD | Sell S | September 2, 2026 | September 4, 2026 | 2d | 970 | $235 | $228K | 10b5-1 plan | Form 4 ↗ | |
| RMD | Sell S | August 5, 2026 | August 6, 2026 | 1d | 8,000 | $225 | $1.8M | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 4, 2026 | Form 4 | 0000943819-26-000050 | 1 | published | EDGAR ↗ |
| August 6, 2026 | Form 4 | 0000943819-26-000040 | 1 | published | EDGAR ↗ |
Other insiders at RESMED INC
- Farrell Michael J. Director 17 rows
- Bloomer Aaron Chief Financial Officer 1 row
- Leong Justin Chief Product Officer 1 row
- Rider Michael J Global General Counsel 1 row
Everyone on file, with contracts and lobbying under the company's name: RESMED INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | August 6, 2026 | September 4, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.